Rating Change
Chardan Capital analysts initiated coverage on Tvardi Therapeutics, Inc. (NASDAQ:TVRD) with a rating of Buy on October 20, 2026.
new coverageNASDAQ:TVRD
Chardan Capital Initiates Coverage on Tvardi Therapeutics, Inc. (TVRD) with Buy
Chardan Capital analysts initiated coverage on Tvardi Therapeutics, Inc. (NASDAQ:TVRD) with a rating of Buy on October 20, 2026.
At publication ·
What changed
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) · new coverage
- Firm
- Chardan Capital
- Rating
- Buy
- Price at event
- $0.99
- Market capitalization
- $42.1M
At a glance
Key takeaways
- Chardan Capital initiated Buy coverage on Tvardi Therapeutics (TVRD) on October 20, 2026, while the stock trades at $0.99 with a $42.1M market capitalization.
Market Context
Tvardi Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $0.99 with a market capitalization of $42.1M. The stock has declined 84.9% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tvardi Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tvardi Therapeutics, Inc.
Among the 10 most recent ratings: 6 Buy, 3 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 20, 2026 | Chardan Capital | Buy | N/A |
| Jul 30, 2026 | BTIG | Buy | N/A |
| Jul 08, 2026 | Raymond James | Outperform | N/A |
| Jul 07, 2026 | BTIG | Buy | N/A |
| Jun 08, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TVRD Stock Page
Frequently Asked Questions
What does the Buy rating mean for TVRD?
A rating of Buy from Chardan Capital reflects the analyst's outlook on Tvardi Therapeutics, Inc. (NASDAQ:TVRD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TVRD forecast page.